48 results about "Tumor antigen" patented technology

The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of. (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.

Lung cancer remains the leading cause of cancer-related deaths in the world. Despite the fact that introduction of immune checkpoint inhibitors (ICIs) led to a major advancement in lung cancer treatment, disease prognosis continues to remain low and a significant proportion of patients do not respond to such therapies. Cancer vaccines could potentially provide a complementary approach to boost antitumor immunity and act synergistically with ICIs. Novel tumor antigens shared by a large proportion of lung tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.

This invention discloses a universal detection method for tumor antigen-specific thymus-dependent lymphocytes in a broad population of East Asia, applicable to lung cancer and gastrointestinal cancers. The broad-spectrum T-cell epitope peptide library used in this detection method contains specific antigen T-cell epitope peptides presented by 13 HLA-A molecules, 15 HLA-B molecules, and 14 HLA-C molecules with an allele frequency greater than 1% in the East Asian population. The total gene frequencies of these dominant HLA-A, B, and C molecules account for approximately 95%, 71%, and 93% of the Chinese population, respectively, and are similar in total gene frequencies in Northeast and Southeast Asian populations. Therefore, this detection method is applicable to the vast majority of individuals in this region, providing a universal method for evaluating specific tumor antigen-specific T-cell immune function in patients with lung cancer or gastrointestinal tumors.

Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.

The invention is directed to methods for determining antigen-specific T cells generally and to T cell receptors which bind an epitope of the Wilms' tumor antigen-1 (WT1) protein specifically. The disclosure also provides polynucleotides encoding the TCRs, engineered cells exogenously expressing the TCRs, and methods of making and using the TCRs and / or cells expressing the TCRs.

The present invention relates to a nucleic acid molecule encoding a multispecific antigen-binding protein and exhibiting significantly improved expression efficiency in vivo. In the multispecific antigen-binding protein of the present invention, specifically, a bispecific antibody that recognizes a tumor antigen or a viral antigen and a natural killer cell-specific activating receptor, the light chain variable region (VL) and the heavy chain variable region (VH) of a receptor-recognizing site of a natural killer cell-specific activating receptor are sequentially arranged in the N-terminus to the C-terminus direction, thereby increasing expression efficiency by up to 8-fold. Therefore, the present invention provides an optimal mRNA structure capable of most efficiently expressing bispecific antibodies in vitro and in vivo, thereby enabling effective use thereof for not only mass-production of recombinant bispecific antibodies but also as an excellent mRNA therapeutic agent for stable and continuous production of a therapeutically effective amount of bispecific antibodies in the body of a patient.

The present invention provides a composite molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and uses of the composite molecule, the nucleic acid, the vector, the host cell, and the pharmaceutical composition in preparation of drugs for treating cancers. The composite molecule comprises an anti-tumor antibody domain, a linker, and pro-IL-15; the anti-tumor antibody domain is linked to the pro-IL-15 by means of the linker; the anti-tumor antibody domain is a complete antibody against an immune checkpoint molecule, a tumor antigen molecule or an immune activation molecule, or a nano antibody or an antigen binding fragment thereof; the linker is a polypeptide linker or a non-peptide linker; the pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, and a linker peptide, and optionally comprising an IL-15Rβ extracellular domain; and the IL-15Rβ extracellular domain, the IL-15, and the IL-15Rα sushi domain are linked by means of the linker peptide.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

This invention discloses a multifunctional engineered NK cell, its construction method, and its applications. This NK cell co-expresses a membrane-bound targeted cytokine complex and a secretory bispecific nanobody via a single-carrier system. The membrane-bound complex uses an anti-PD-L1 single-domain antibody to directionally anchor IL-15 / IL-21 to the cell membrane surface and utilizes synaptic recruitment to achieve high-level enrichment of cytokine signals at the immune synapse, enabling precise paracrine secretion of cytokine signals. The secretory bispecific antibody mediates specific cytotoxicity by transdirectionally linking the NK cell activation receptor NKp46 with the tumor-associated antigen B7-H3. Experiments have demonstrated that the engineered NK cells constructed in this invention significantly enhance the killing efficacy against PD-L1 or B7-H3 positive tumor cells while maintaining a high P2A cleavage rate, and the synergistic index shows a significant synergistic effect. This invention effectively overcomes the technical shortcomings of traditional NK cell therapy, such as systemic cytokine toxicity and tumor antigen escape, providing a novel strategy for immunotherapy of solid tumors.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The application provides anti-CD28 nanobodies and uses thereof, and belongs to the technical field of biotechnology. Specifically disclosed are several CD28-targeted nanobodies, coding sequences and expression vectors for producing the nanobodies, and application of the nanobodies in preparation of tumor treatment drugs. The nanobodies can not only specifically recognize and bind to CD28, laying a foundation for subsequent development of antibody conjugated drugs and multi-specific antibodies, but also can be combined with tumor antigen-targeted antibodies to form multi-specific antibodies, and the formed multi-specific antibodies significantly enhance the ability of activated T cells and the activity of killing tumor cells.

The present invention provides synthetic polypeptides comprising an annexin V protein, or a functional portion or fragment or variant thereof, conjugated to a tumor antigen, or a functional portion or fragment or variant thereof. The invention further provides methods for making said synthetic polypeptides and their use in the treatment of proliferative diseases such as cancer and tumors originating therefrom.

This invention relates to the field of biomedical technology, specifically disclosing a gene modification method for enhancing TCR-T cell activity and its application in tumor treatment. The method includes the following steps: T cells are activated in vitro; gene editing is performed to knock out endogenous immune checkpoint genes; a recombinant expression vector is constructed, the vector containing a polycistronic expression cassette driven by a single promoter, wherein the nucleic acid sequence encoding TCR and the nucleic acid sequence encoding an immunomodulatory factor are tandemly linked by a self-cleaving peptide coding sequence; the recombinant expression vector is introduced into the gene-knockout T cells; and the transduced T cells are cultured and expanded to obtain TCR-T cells with enhanced activity. This invention significantly enhances the anti-tumor activity, in vivo persistence, and tumor infiltration capacity of TCR-T cells through the synergistic effect of knocking out immune checkpoint genes and autocrine immunomodulatory factors; its modular design allows for flexible adaptation to different tumor antigen targets.

The application belongs to the technical field of cell engineering, and particularly relates to a bispecific antibody targeting CD22 and CD19, a chimeric antigen receptor thereof and application. In the bispecific antibody, a CD22 light chain and a CD22 heavy chain are connected through a linker 4 to form a CD22 single-chain antibody, and a CD19 light chain and a CD19 heavy chain are connected through a linker 4 to form a CD19 single-chain antibody, which comprises one of the following structures: (1) the CD22 single-chain antibody and the CD19 single-chain antibody are connected through a linker 1 or a liner 2; (2) the two ends of the CD19 single-chain antibody are connected with the CD22 light chain and the CD22 heavy chain through a linker 3, respectively. The chimeric antigen receptor provided by the application can simultaneously target two different tumor antigens, improve the killing of tumor cells, reduce the probability of immune escape, and reduce the tumor recurrence rate after CAR-T treatment.

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are genetically edited, for example, using Crispr / Cas, to modulate, reduce or otherwise eliminate expression of one or more endogenous genes. In several embodiments, the edited cells are engineered to express a chimeric antigen receptor targeting a tumor antigen, for example CD19, ligands of the NKG2D receptor, CD70, and / or BCMA, among others. In several embodiments, the editing enhances one or more aspects of the efficacy of the immune cells in cellular immunotherapy including cytotoxicity (e.g., ADCC) and / or persistence.

This invention provides a method for mining tumor antigens derived from endogenous retroviruses. The method involves bulk RNA-seq sequencing of tumor tissue and adjacent normal tissue samples using a splicing strategy to obtain DNA sequences of human endogenous retrovirus (HERV)-derived transcripts (hervRNA). Subsequently, a specific screening strategy is employed to obtain candidate open reading frames (ORF) sequences on tumor-specific hervRNAs. Finally, homology analysis, prediction of binding energy to human leukocyte antigen class I (HLA-I) molecules, and multi-site analysis are used to predict and mine neoantigens derived from HERV in tumors.

The application relates to the technical field of biological medicine, in particular to an anti-GPC3 antibody and application thereof, the anti-GPC3 antibody, code B174, comprises a heavy chain variable region, the anti-GPC3 antibody heavy chain variable region comprises CDR-H1 with the amino acid sequence as shown in SEQ ID No. 1, CDR-H2 as shown in SEQ ID No. 2 and CDR-H3 with the amino acid sequence AADIVRYYCSGYVVPDDYGV. The anti-GPC3 antibody has high affinity and specificity, can effectively target tumor antigen GPC3, and is used for preparing a chimeric antigen receptor by using the anti-GPC3 antibody, and further preparing a chimeric antigen receptor cell, the chimeric antigen receptor cell can efficiently kill tumor cells, and has high specificity.

This document provides methods and materials for assessing a mammal having or suspected of having cancer and / or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-chain variable fragment (scFv)) that can bind to a modified peptide (e.g., a tumor antigen), as well as method for using such molecules, are provided.

The present disclosure provides a modified bispecific molecule that targets (a) a tumor-specific mutant peptide or mutation-associated neoantigen (MANA) presented by human leukocyte antigens (HLA) on the surface of target cancer cells; and (b) a surface protein (e.g., CD3) expressed on effector immune cells (e.g., T cells), as well as a method of using the molecule in cell therapy to diagnose, prevent, and / or treat human diseases including cancer. The bispecific molecule is modified to additionally include domain orientation modifications, linker modifications, and functional moieties including, e.g., Fc fragments, serum albumin, and / or polyethylene glycol (PEG) groups, which can improve efficacy, therapeutic index, half-life, and ease of manufacture while maintaining functionality and specificity in the treatment of diseases such as cancer.

The present invention relates to tumor antigens or cancer antigens, particularly amino acid sequences and nucleic acid sequences, which may be used in cancer immunotherapy. In particular, the present invention relates to artificial nucleic acids, preferably RNA, comprising at least one coding sequence encoding at least one tumor antigen or cancer antigen. The tumor antigen or cancer antigen is Peptides or proteins encoded by small open reading frames (smORFs) of long non-coding RNA (IncRNA), or The fragment or variant thereof, At least one antigenic peptide selected from or derived therefrom, and / or Tumor neoantigen peptides or proteins, or The fragment or variant thereof, at least one antigenic peptide selected from or derived therefrom The invention provides a pharmaceutical composition comprising or consisting of the artificial nucleic acid, preferably formulated within a lipid-based carrier. It also provides a method for treating or preventing a disease, disorder, or condition, and medical applications for treating or preventing cancer in particular (such as NSCLC, HNSCC, or melanoma).

This invention discloses a ginsenoside membrane hybrid tumor nanovaccine, a pharmaceutical composition, its preparation method, and its applications. The ginsenoside membrane hybrid tumor nanovaccine comprises a fusion membrane formed by a macrophage membrane and a lipid membrane; wherein, a tumor antigen peptide-MHC complex is bound to the surface of the macrophage membrane, and the lipid membrane comprises ginsenosides and phospholipids. This ginsenoside membrane hybrid tumor nanovaccine and the pharmaceutical composition containing it simultaneously possess excellent effects such as high antigenicity, broad-spectrum activity, high targeting, high adjuvant potency, and safety, demonstrating superior efficacy in practical applications; furthermore, the entire preparation process is simple to operate and has good reproducibility.

This invention discloses a manganese-mineralized full-component tumor vaccine, its preparation method, and its application. The invention first synthesizes a guanidine-containing cationic monomer and obtains a block copolymer of guanidine monomer / acrylic acid monomer via reversible addition-fragmentation chain transfer radical polymerization (RAFT). Phosphoric acid / phosphonic acid compounds are grafted using an EDC / NHS coupling reaction to prepare a polymer carrier. A full-component tumor antigen is prepared through repeated freeze-thaw cycles and ultrasonic lysis. The tumor antigen is loaded onto the synthesized polymer carrier and finally prepared as a full-component tumor vaccine after manganese surface mineralization treatment. In this invention, the guanidine-containing structure of the polymer carrier can capture the antigen and self-assemble into nanoparticles. Simultaneously, the phosphate / phosphonic acid groups can efficiently chelate manganese ions, providing mineralization sites and achieving the co-delivery of the full-component tumor antigen and manganese adjuvant.

The application belongs to the field of biology and provides a tumor antigen peptide, an antibody, a detection kit, a pharmaceutical composition or a vaccine and uses thereof, wherein the amino acid sequence of the tumor antigen peptide is shown as SEQ ID NO:1; or the tumor antigen peptide is a functional derivative of SEQ ID NO:1, the derivative has a core epitope of SEQ ID NO:1 and comprises one or more of the following modifications: 1) N-terminal or C-terminal modification; 2) amino acid substitution or length variation; 3) connection with other peptide segments to form a polyepitope peptide; 4) cyclization, PEGylation, fatty acidation or linker peptide modification. The antigen peptide provided by the application shows good immunogenicity and anti-tumor activity in an in vitro model and can be used as a key active component in the preparation of a novel tumor vaccine, TCR-T cell therapy or an immune adjuvant.

The application relates to the technical field of biological medicine, in particular to an anti-GTR2-2 antibody and application thereof, the anti-GTR2-2 antibody is coded as B89, B108 and B168, the heavy chain variable region of the anti-GTR2-2 antibody comprises CDR-H1 with an amino acid sequence as shown in SEQ ID No. 1, SEQ ID No. 23 or SEQ ID No. 34, CDR-H2 as shown in SEQ ID No. 2, SEQ ID No. 24 or SEQ ID No. 36 and CDR-H3 as shown in SEQ ID No. 3, SEQ ID No. 25 or SEQ ID No. 38. The anti-GTR2-2 antibody has high affinity, can effectively target tumor antigen GTR2-2, the chimeric antigen receptor cell prepared by using the anti-GTR2-2 antibody can efficiently kill tumor cells, and has high specificity.

The present disclosure relates to multispecific antibodies that specifically bind to GPRC5D and / or BCMA tumor antigen and T cell surface antigen CD3, as well as pharmaceutical compositions comprising the same, uses and clinical therapeutic applications.

This invention relates to heterodimeric antibodies that bind CD3 and tumor antigens. The heterodimeric antibody comprises: a) a first monomer comprising a first heavy chain, b) a second monomer comprising a second heavy chain, and b) a common light chain; the heterodimeric antibody binds to a target tumor antigen and human CD3.

Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is still largely unknown. Novel tumor antigens shared by a large proportion of ovarian tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also describe

The present disclosure relates to a multispecific antibody that specifically binds to GPRC5D and / or BCMA tumor antigens and a T cell surface antigen CD3, and a pharmaceutical composition comprising the antibody, a use of the antibody, and a clinical therapeutic application of the antibody.

This invention discloses a composition for treating solid tumors. The composition comprises engineered bacteria and one or more azide-based non-natural sugars. The azide-based non-natural sugars are used to label tumor antigens, and the engineered bacteria are used to specifically bind to and deliver the labeled tumor antigens, activating dendritic cells. Application of this composition significantly improves the presentation efficiency of tumor antigens by dendritic cells, thereby enhancing the immune response and demonstrating significant therapeutic efficacy in the treatment of solid tumors.